Current role of therapy with amphotericin B

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• Systemic antifungal chemotherapy is complex due to shared eukaryotic biosynthetic pathways and a limited arsenal of effective agents.
• Standardization of in vitro susceptibility testing and clinical correlation for antifungal therapies remain significant challenges.
• Amphotericin B, despite its known limitations, has been a cornerstone intravenous antifungal agent for over three decades.

Purpose of the Study:

• To review the current clinical utility of Amphotericin B in treating systemic fungal infections.
• To discuss the challenges associated with systemic antifungal chemotherapy.
• To highlight the need for further controlled clinical trials comparing Amphotericin B with newer antifungal agents.

Main Methods:

• Literature review of established and emerging systemic antifungal therapies.
• Analysis of the clinical role and limitations of Amphotericin B.
• Discussion of in vitro susceptibility testing and clinical correlation challenges.

Main Results:

• Amphotericin B continues to be a primary treatment option for numerous systemic fungal infections.
• Significant challenges persist in antifungal drug development and standardized clinical application.
• Existing data highlights the need for comparative trials against newer azoles and lipid formulations of Amphotericin B.

Conclusions:

• Amphotericin B maintains its status as a critical agent in systemic antifungal chemotherapy.
• Further research, particularly controlled clinical trials, is essential to optimize antifungal treatment strategies.
• Comparative studies involving azoles, liposomal Amphotericin B, and Amphotericin B complexes are warranted.